Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial.

Domino ME, Foster EM, Vitiello B, Kratochvil CJ, Burns BJ, Silva SG, Reinecke MA, March JS.

J Am Acad Child Adolesc Psychiatry. 2009 Jul;48(7):711-20. doi: 10.1097/CHI.0b013e3181a2b319.

PMID:
19465880
2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
3.

Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan.

Sado M, Knapp M, Yamauchi K, Fujisawa D, So M, Nakagawa A, Kikuchi T, Ono Y.

Aust N Z J Psychiatry. 2009 Jun;43(6):539-47. doi: 10.1080/00048670902873664. Review.

PMID:
19440886
4.

Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents with depression study.

Pathak S, Kratochvil CJ, Rogers GM, Silva S, Vitiello B, Weller EB, March JS.

Curr Psychiatry Rep. 2005 Dec;7(6):429-34. Review.

PMID:
16318820
5.

Nonsomatic treatment of depression.

Sherrill JT, Kovacs M.

Child Adolesc Psychiatr Clin N Am. 2002 Jul;11(3):579-93. Review.

PMID:
12222084
6.

Clinical messages from the Treatment for Adolescents With Depression Study (TADS).

March JS, Vitiello B.

Am J Psychiatry. 2009 Oct;166(10):1118-23. doi: 10.1176/appi.ajp.2009.08101606. Epub 2009 Sep 1. Review.

PMID:
19723786
7.

[Childhood and adolescent depression].

Mikami K, Matsumoto H.

Nihon Rinsho. 2007 Sep;65(9):1679-83. Review. Japanese.

PMID:
17876994
8.

Modelling the cost-effectiveness of pharmacotherapy compared with cognitive-behavioural therapy and combination therapy for the treatment of moderate to severe depression in the UK.

Koeser L, Donisi V, Goldberg DP, McCrone P.

Psychol Med. 2015 Oct;45(14):3019-31. doi: 10.1017/S0033291715000951. Epub 2015 Jun 4. Review.

PMID:
26040631
9.

Cost-effectiveness of venlafaxine for the treatment of major depression in hospitalized patients.

Priest RG.

Clin Ther. 1996 Mar-Apr;18(2):347-58; discussion 302. Review.

PMID:
8733994
10.

Cost-utility analyses of cognitive-behavioural therapy of depression: a systematic review.

Brettschneider C, Djadran H, Härter M, Löwe B, Riedel-Heller S, König HH.

Psychother Psychosom. 2015;84(1):6-21. doi: 10.1159/000365150. Epub 2014 Dec 24. Review.

PMID:
25547334
11.

The importance of achieving additional drug benefits at a reasonable cost. A review of the fluoxetine years.

Freemantle N, Mason J.

Pharmacoeconomics. 2000 Apr;17(4):319-24. Review.

PMID:
10947486
12.

[Practice guideline for the treatment of mood disorders].

Higuchi T.

Nihon Rinsho. 2007 Sep;65(9):1627-32. Review. Japanese.

PMID:
17876985
13.

[Evaluation of behavioral and cognitive therapy in depression].

Mirabel-Sarron C.

Bull Acad Natl Med. 2010 Mar;194(3):605-15; discussion 615. Review. French.

PMID:
21171253
14.

The use of cognitive behavioral therapy in the treatment of resistant depression in adolescents.

Hamill-Skoch S, Hicks P, Prieto-Hicks X.

Adolesc Health Med Ther. 2012 Sep 10;3:95-104. doi: 10.2147/AHMT.S13781. eCollection 2012. Review.

Supplemental Content

Support Center